H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Acer Therapeutics (ACER – Research Report) today and set a price target of $12.00. The company’s shares opened today at $0.77.
Bernardino covers the Healthcare sector, focusing on stocks such as Novavax, GeoVax Labs, and Edesa Biotech. According to TipRanks, Bernardino has an average return of 14.1% and a 29.51% success rate on recommended stocks.
Acer Therapeutics has an analyst consensus of Hold.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.56 and a one-year low of $0.65. Currently, Acer Therapeutics has an average volume of 468.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling in September 2017 and is headquartered in Newton, MA.
Read More on ACER:
- Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update
- Biotech Alert: Searches spiking for these stocks today
- Acer Therapeutics: Data presented at SIMD on Urea Cycle Disorders
- Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
- Acer Therapeutics prices $2.68M registered direct offering
